CO6241115A2 - Compuestos y composiciones como inhibidores de protein quinasas - Google Patents

Compuestos y composiciones como inhibidores de protein quinasas

Info

Publication number
CO6241115A2
CO6241115A2 CO09044589A CO09044589A CO6241115A2 CO 6241115 A2 CO6241115 A2 CO 6241115A2 CO 09044589 A CO09044589 A CO 09044589A CO 09044589 A CO09044589 A CO 09044589A CO 6241115 A2 CO6241115 A2 CO 6241115A2
Authority
CO
Colombia
Prior art keywords
halo
substituted
6alkyl
6alkoxy
independently selected
Prior art date
Application number
CO09044589A
Other languages
English (en)
Inventor
Donatella Chianelli
Xiaolin Li
Xiaodong Liu
Jon Loren
Valentina Molteni
Juliet Nabakka
Laszlo Revesz
Lawrence B Perez
Clinton Brooks
Wojciech Wrona
Paul W Manley
Werner Breitenstein
Original Assignee
Irm Llc
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc, Novartis Ag filed Critical Irm Llc
Publication of CO6241115A2 publication Critical patent/CO6241115A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

1.- Un compuesto de Fórmula I:en donde X se selecciona de un enlace y NH; Y se selecciona de un enlace y NH; R1 se selecciona de ciclohexil, piridinil, quinolinil, isoquinolinil y fenil; donde dicho ciclohexil, piridinil, quinolinil, isoquinolinil o fenil de R1 puede estar opcionalmente sustituido con 1 un 3 radicales independientemente seleccionado de halo, C1-6alquil, C1-6alcoxi, halo-sustituido-C1-6alquil, halo-sustituido-C1-6alcoxi, -NR5aR5b, OX1NR5aR5b y heterociclil; donde X1 es independientemente seleccionado de un enlace y C1-4alquileno; y R5a y R5b son independientemente seleccionados de hidrógeno, C1-6alquil, C1-6alcoxi, halo-sustituido-C1-6alquil y halo-sustituido-C1-6alcoxi; R2 se selecciona de halo, C1-6alquil, C1-6alcoxi, halo-sustituido-C1-6alquil y halo-sustituido-C1-6alcoxi; R3 se selecciona de halo, C1-6alquil, C1-6alcoxi, halo-sustituido-C1-6alquil y halo-sustituido-C1-6alcoxi; R4 es heteroaril sustituido con 1 un 3 radicales independientemente seleccionado de halo, ciano, C1-6alquil, C1-6alcoxi, halo-sustituido-C1-6alquil, halo-sustituido-C1-6alcoxi, C6-10aril-C0-4alquil, heteroaril, heterociclil, -X1NR5R5, -X1NR5OR5, -X1NR5X1OR5, -X1NR5X1C(O)NR5R5, -X1S(O)2NR5R5, -X1S(O)2R5, -X1NR5R5, -X1NR5OR5, -X1C(O)R5, -X1OX2OR5, -OX1R5, -X1R5, -X1C(O)OR5, -X1OR5 y -X1OX1OR5; donde cada X1 es independientemente seleccionado de un enlace y C1-4alquileno; X2 es C1-4alquileno; y cada R5 es independientemente seleccionado de hidrógeno, C1-6alquil, C2-6alquenil, C3-12cicloalquil, C6-10aril-C0-4alquil, heteroaril-C0-4alquil y heterociclil;donde dicho aril, cicloalquil, heteroaril o heterociclil sustituyentes de R4 puede opcionalmente estar adicionalmente sustituido con 1 a 3 radicales independientemente seleccionado de halo, hidroxi, ciano, C1-6alquil, C1-6alcoxi, halo-sustituido-C1-6alquil, halo-sustituido-C1-6alcoxi, -L-OR6, -L-C(O)OR6, -L-C(O)NR6R6 y -L-R6; donde L se selecciona de un enlace y C1-4alquileno; y R6 se selecciona de hidrógeno, C1-6alquil y heterociclil; con la condición que R4 no es piridin-3-il sustituido por un radical trifluormetil; y sales farmacéuticamente aceptables del mismo.
CO09044589A 2006-11-03 2009-05-04 Compuestos y composiciones como inhibidores de protein quinasas CO6241115A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86437806P 2006-11-03 2006-11-03

Publications (1)

Publication Number Publication Date
CO6241115A2 true CO6241115A2 (es) 2011-01-20

Family

ID=39119736

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09044589A CO6241115A2 (es) 2006-11-03 2009-05-04 Compuestos y composiciones como inhibidores de protein quinasas

Country Status (20)

Country Link
US (1) US20100048539A1 (es)
EP (1) EP2079729A1 (es)
JP (1) JP2010509349A (es)
KR (2) KR20120049397A (es)
CN (1) CN101622244A (es)
AU (1) AU2007317349B2 (es)
BR (1) BRPI0718677A2 (es)
CA (1) CA2668190A1 (es)
CO (1) CO6241115A2 (es)
CR (1) CR10755A (es)
EA (1) EA200970447A1 (es)
EC (1) ECSP099378A (es)
IL (1) IL198315A0 (es)
MA (1) MA30906B1 (es)
MX (1) MX2009004716A (es)
NO (1) NO20092138L (es)
RU (1) RU2009120882A (es)
SM (1) SMAP200900031A (es)
TN (1) TN2009000163A1 (es)
WO (1) WO2008058037A1 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8735415B2 (en) 2004-09-09 2014-05-27 Natco Pharma Limited Acid addition salts of (3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide
MX2007002819A (es) * 2004-09-09 2007-08-14 Natco Pharma Ltd Nuevos derivados de fenilaminopirimidina como inhibidores de bcl-abl cinasa.
PT2035369E (pt) 2006-07-05 2014-09-30 Fibrotech Therapeutics Pty Ltd Compostos terapêuticos
WO2008137794A1 (en) 2007-05-04 2008-11-13 Irm Llc Compounds and compositions as c-kit and pdgfr kinase inhibitors
TWI433677B (zh) * 2007-06-04 2014-04-11 Avila Therapeutics Inc 雜環化合物及其用途
KR20120107538A (ko) 2007-08-22 2012-10-02 아이알엠 엘엘씨 키나제 억제제로서의 5-(4-(할로알콕시)페닐)피리미딘-2-아민 화합물 및 조성물
BRPI0815572A2 (pt) 2007-08-22 2015-02-18 Irm Llc Compostos e composições como inibidores de quinases
CN102123711A (zh) * 2008-08-13 2011-07-13 诺瓦提斯公司 肺动脉高压的治疗
UA103918C2 (en) 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
CN102341102A (zh) * 2009-03-06 2012-02-01 诺瓦提斯公司 嘧啶基氨基苯甲酰胺衍生物用于治疗由包含亮氨酸拉链和不育α基序的激酶(ZAK)介导的疾病的用途
IN2012DN03312A (es) * 2009-10-22 2015-10-23 Fibrotech Therapeutics Pty Ltd
CA3034600C (en) * 2010-05-07 2020-11-10 Genentech, Inc. Pyridone and aza-pyridone compounds and methods of use
MX367469B (es) 2010-06-07 2019-08-23 Novomedix Llc Compuestos furanilo y su uso.
AU2011331161A1 (en) * 2010-11-17 2013-05-02 Novartis Ag 3-(aminoaryl)-pyridine compounds
WO2013022766A1 (en) * 2011-08-05 2013-02-14 Flynn Gary A Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors
EP2751104B1 (en) * 2011-09-01 2019-09-25 Novartis AG Compounds and compositions as c-kit kinase inhibitors
US20150011508A1 (en) * 2011-09-01 2015-01-08 Irm Llc Compounds and compositions as c-kit kinase inhibitors
US9199981B2 (en) * 2011-09-01 2015-12-01 Novartis Ag Compounds and compositions as C-kit kinase inhibitors
UY34305A (es) 2011-09-01 2013-04-30 Novartis Ag Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
WO2014170350A1 (en) * 2013-04-17 2014-10-23 Albert Ludwigs Universität Freiburg Compounds for use as bromodomain inhibitors
CN103288804A (zh) * 2013-05-24 2013-09-11 苏州明锐医药科技有限公司 一种尼洛替尼的制备方法
US10562912B2 (en) 2013-06-05 2020-02-18 C&C Research Laboratories Heterocyclic derivatives and use thereof
US20170000784A1 (en) * 2013-12-08 2017-01-05 Van Andel Research Institute Autophagy Inhibitors
SG11201607267SA (en) 2014-03-07 2016-09-29 Biocryst Pharm Inc Human plasma kallikrein inhibitors
CN105085489B (zh) * 2014-11-05 2019-03-01 益方生物科技（上海）有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
CN106187995A (zh) * 2015-05-05 2016-12-07 天津国际生物医药联合研究院 含酰胺键杂环类化合物及其制备方法和应用
MX2018002337A (es) * 2015-09-04 2018-07-06 Dow Agrosciences Llc Moleculas que tienen utilidad plaguicida, e intermediarios, composiciones y procesos, relacionados con ellas.
AU2016326718B2 (en) * 2015-09-23 2022-12-15 Minerva Biotechnologies Corporation Method of screening for agents for differentiating stem cells
PL3426244T3 (pl) * 2016-03-09 2023-09-25 Raze Therapeutics, Inc. Inhibitory dehydrogenazy 3-fosfoglicerynianowej i ich zastosowania
WO2017156165A1 (en) 2016-03-09 2017-09-14 Raze Therapeutics, Inc. 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
CN105974131B (zh) * 2016-06-16 2017-12-26 武汉大学 c‑Kit作为药物成瘾治疗靶点的应用
RU2019121922A (ru) * 2016-12-15 2021-01-18 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Композиции и способы лечения рака
US11014873B2 (en) 2017-02-03 2021-05-25 Certa Therapeutics Pty Ltd. Anti-fibrotic compounds
JP6994715B2 (ja) * 2017-10-04 2022-02-04 国立大学法人京都大学 Ｂｃｒ－Ａｂｌタンパク質イメージング用分子プローブ
CN108187052B (zh) * 2018-02-05 2021-06-08 苏州大学 Akt抑制剂在制备治疗血小板数量减少相关疾病药物中的用途
EP4181921A1 (en) 2020-07-15 2023-05-24 Third Harmonic Bio, Inc. Crystalline forms of a selective c-kit kinase inhibitor
US11629143B2 (en) 2020-10-01 2023-04-18 Vibliome Therapeutics, Llc HipK4 inhibitors and uses thereof
US11744823B2 (en) 2020-11-19 2023-09-05 Third Harmonic Bio, Inc. Pharmaceutical compositions of a selective c-kit kinase inhibitor and methods for making and using same
CN113797345B (zh) * 2021-10-22 2023-05-16 北京大学人民医院 糖皮质激素与糖酵解调节剂在制备急性移植物抗宿主病的药物中的应用
WO2023212612A2 (en) * 2022-04-27 2023-11-02 Qian Shawn Certain chemical entities, compositions, and methods

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE331519T1 (de) * 2001-05-16 2006-07-15 Gpc Biotech Ag Pyridylpyrimidin-derivate als wirksame verbindungen gegen prionen-krankheiten
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GB0222514D0 (en) * 2002-09-27 2002-11-06 Novartis Ag Organic compounds
MX2007002819A (es) * 2004-09-09 2007-08-14 Natco Pharma Ltd Nuevos derivados de fenilaminopirimidina como inhibidores de bcl-abl cinasa.
EP1835934A4 (en) * 2004-12-23 2010-07-28 Deciphera Pharmaceuticals Llc ENZYME MODULATORS AND TREATMENTS
AU2005325676A1 (en) * 2004-12-23 2006-08-03 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
KR100674813B1 (ko) * 2005-08-05 2007-01-29 일양약품주식회사 Ｎ-페닐-2-피리미딘-아민 유도체 및 그의 제조방법

Also Published As

Publication number Publication date
JP2010509349A (ja) 2010-03-25
MX2009004716A (es) 2009-07-17
AU2007317349B2 (en) 2011-10-20
EA200970447A1 (ru) 2009-10-30
SMAP200900031A (it) 2009-07-14
AU2007317349A1 (en) 2008-05-15
TN2009000163A1 (en) 2010-10-18
ECSP099378A (es) 2009-07-31
CN101622244A (zh) 2010-01-06
WO2008058037A1 (en) 2008-05-15
RU2009120882A (ru) 2010-12-10
KR20120049397A (ko) 2012-05-16
MA30906B1 (fr) 2009-11-02
NO20092138L (no) 2009-07-13
BRPI0718677A2 (pt) 2013-11-26
KR20090075889A (ko) 2009-07-09
IL198315A0 (en) 2010-02-17
CA2668190A1 (en) 2008-05-15
CR10755A (es) 2009-06-04
US20100048539A1 (en) 2010-02-25
EP2079729A1 (en) 2009-07-22

Similar Documents

Publication Publication Date Title
CO6241115A2 (es) Compuestos y composiciones como inhibidores de protein quinasas
TW200738684A (en) Novel sulfated cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
UA101036C2 (en) Substituted 1-(diazinyl) pyrazole-4-yl-acetic acids
HRP20080113T3 (en) Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
CY1114083T1 (el) Συνδυασμος μιας ενωσης της 5-φαινυλοθειαζολης ως αναστολεας της κινασης pi3 με ενα αντιφλεγμονωδες, βρογχοδιασταλτικο ή αντιισταμινικο φαρμακo
EA200801608A1 (ru) Производные бензимидазолонкарбоновой кислоты
MX2016006685A (es) Compuestos heterociclicos de n-acilimino.
CY1112914T1 (el) Υποκατεστημενα παραγωγα ινδολυλ αλκυλ αμινης ως νεοι αναστολεις των αποακετυλασων ιστονης
MX2009009774A (es) Derivados de quinolina como fungicidas.
IN2012DN00709A (es)
CO6680665A2 (es) Derivados de 5-yodo-triazol
BR112013023603A2 (pt) n-(1,2,5-oxadiazol-3-il)piridinacarboxamidas e seu emprego como herbicidas
CY1109854T1 (el) Παραγωγα αζαδικυκλο(3.1.0)εξανιου χρησιμα ως ρυθμιστες υποδοχεων d3 ντοπαμινης
TW200618800A (en) Heterocyclic compounds
MX2011011875A (es) Compuesto de carboxamida heterociclica diamino.
DK1761520T3 (da) Kinaseinhibitorer
CO6241190A2 (es) Compuestos para inhibicion enzimatica
ATE529402T1 (de) 3',6-substituierte indirubine und ihre biologischen anwendungen
TW200728277A (en) Bicyclic derivatives as P38 inhibitors
TW200640862A (en) Pyridyl acetic acid compounds
ES2662444T3 (es) Derivado de piridina
TW200738685A (en) Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
NO20083923L (no) Pyrazolkinoloner er potente parp-inhibitorer
AR078270A1 (es) Inhibidores de jak (quinasas janus)
AR057929A1 (es) Compuestos de amidinfenilo y su uso como fungicidas

Legal Events

Date Code Title Description
FA Application withdrawn